BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles
Formulated with a double dose of BioHarvest's proprietary red grape cell composition, VINIA® DailyChews 2X Formula are officially Informed Sport-certified, underscoring the Company's commitment to cleaner, safer, and effective performance nutrition. The globally recognized certification ensures every batch is tested for banned substances, making it a trusted choice for professional athletes, military personnel, and fitness enthusiasts alike.
Each individually packaged VINIA® DailyChews 2X Formula contains 800mg of VINIA® and 12 mg of Piceid resveratrol, which has been clinically shown to increase arterial dilation. This arterial dilation improves blood flow, delivering more oxygen and nutrients to the body's muscles, tissues, and cells, improving physical energy and mental alertness.*
'Our customers lead dynamic, high-performance lives, and they deserve a product that meets the highest standards for efficacy, safety and ease of use,' said Ilan Sobel, CEO of BioHarvest. 'The launch of VINIA® DailyChews 2x Formula - with Informed Sport certification - marks a major milestone as we expand into the athlete and fitness enthusiast segment of the multi-billion-dollar nutraceuticals market and address a younger consumer base. In addition, our new international ecommerce platform enables global orders, so that customers in countries which allow importation of supplements, such as the UK and Australia, can now have VINIA® products delivered directly to their doorstep with local tax and import fee calculations handled automatically on the backend.
'This launch complements our growing VINIA® Inside portfolio, which includes the core capsule business and hot beverage line of teas and coffees, reflecting our broader strategy to meet increasing global demand for plant-based, science-backed solutions,' concluded Sobel.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
About Informed Sport
Informed Sport is the world's leading testing and certification program for brands producing sports and nutritional supplements. Designed for elite sport, it protects athletes from inadvertent doping caused by supplements contaminated with banned substances. As such, it is recognised by sporting and governing bodies, anti-doping bodies and nutrition industry organisations, and the armed and special forces. https://sport.wetestyoutrust.com/
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com .
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
[email protected]
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254440
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
This Artificial Intelligence (AI) Stock Just Dropped, and That's a Buying Opportunity
Key Points The Trade Desk stock slumped after earnings, the second post-earnings drop this year. Shares of the digital ad specialist now sell at a forward price-to-earnings multiple of 30. Artificial intelligence is upgrading the user experience on The Trade Desk's platform. 10 stocks we like better than The Trade Desk › Investors tend to want to avoid stocks after they have made a significant drop. Such price action points to problems investors either did not understand previously or ignored for whatever reason. This is likely the case with The Trade Desk (NASDAQ: TTD) after announcing its earnings for the second quarter of 2025, and the price fell 39% the following trading day. In The Trade Desk's case, investors dealt with elevated expectations and valuations. They have also become increasingly aware of the effects of the "walled gardens" that limit engagement with the largest ad platforms such as Alphabet's Google and Amazon. Despite such concerns, The Trade Desk may still be a buy, and here is why investors should still consider owning this stock that is widening its competitive moat through artificial intelligence (AI). The Trade Desk's Q2 earnings For the second time this year, the stock fell after releasing an earnings report that arguably brought more positives than negatives. Its second-quarter revenue was $694 million, a 19% yearly increase and slightly ahead of analyst expectations. The company also beat analyst estimates on earnings, though the $90 million in net income rose by 6% compared to year-ago levels, primarily due to a 56% in its provision for income taxes. Still, the company's third-quarter revenue forecast of $717 million fell slightly short of expectations. It also implied a 14% yearly growth rate, increasing concerns over the company's long-term growth. The company announced the departure of its chief financial officer. When combined with the increased concerns over the "walled gardens" eating into market share and a pre-announcement price-to-earnings ratio (P/E) of 108, that could have prompted investors to rethink what had become an elevated valuation. This decline slightly surpasses its one-day drop following fourth-quarter earnings, when investors sold the stock after it missed its own revenue target for the quarter. Although The Trade Desk's stock rose after first-quarter earnings, this may undermine investor confidence. Why investors should consider buying The Trade Desk anyway Nonetheless, the sell-off has made the valuation more attractive. The trailing P/E that was 108 has now fallen to 65. Moreover, the stock sells for 31 times forward earnings. Even if revenue growth slows to 14%, that could still prompt rapid net income growth at the same time investors become more accustomed to a tax rate more fitting of a consistently profitable company. Furthermore, AI is on track to supercharge this growth. The company is in the process of switching from Solimar to Kokai. Solimar specializes in optimizing digital ad campaigns, but with the AI-driven Kokai platform, users have a more holistic approach to media buying, applying deep-learning algorithms to every aspect of the process. Thus, Kokai leverages AI for better forecasting, predictive bidding, and impression scoring. Moreover, it enables users to allocate ad budgets more effectively and curate premium ad inventory. And The Trade Desk offers a neutral platform targeting digital ad opportunities on every platform. This lack of bias helps advertisers and ad agencies place ads where they can best perform, unencumbered by biases that a Google or Amazon might have toward those platforms. Furthermore, the numbers are likely lower amid a sluggish economy. Still, that price action is probably cyclical, and the predictions for 17% revenue growth in 2025 and 18% the following year do not point to a significant slowdown. That means growth could easily accelerate, reinforcing the buy case for the stock. The Trade Desk buying opportunity Amid the considerable drop in the stock price, investors have a tremendous opportunity to buy it at a significant discount. Indeed, the sell-off is the second huge post-earnings sell-off over three quarters, and such price behavior could diminish confidence in the stock. However, thanks to the discounted price, the forward P/E of 30 makes the stock particularly attractive. Also, forecasts so far indicate that the slowing to 14% revenue growth may be temporary. Assuming a reacceleration of revenue growth occurs, investors will likely wish they had bought shares at current prices. Should you buy stock in The Trade Desk right now? Before you buy stock in The Trade Desk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and The Trade Desk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Will Healy has positions in The Trade Desk. The Motley Fool has positions in and recommends Alphabet, Amazon, and The Trade Desk. The Motley Fool has a disclosure policy. This Artificial Intelligence (AI) Stock Just Dropped, and That's a Buying Opportunity was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
2 Stocks Down More Than 90% That Still Aren't Worth Buying
Key Points Teladoc Health and Tilray Brands have lost significant value over the past five years. Teladoc is posting slow growth and consistent net losses, with little hope of a turnaround. Tilray faces several roadblocks in the highly regulated cannabis industry. 10 stocks we like better than Teladoc Health › While basic investing wisdom advises us to "buy low," no point is low enough when there's hardly any hope that a stock will bounce back. In other words, no matter how much a company lags the market, sometimes it still isn't attractive. In my view, that's the case with Teladoc Health (NYSE: TDOC) and Tilray Brands (NASDAQ: TLRY), both of which have lost more than 90% of their market value over the past five years. Their stocks still aren't worth buying, though. Here's what investors need to know about these companies. 1. Teladoc Health Teladoc, a telemedicine specialist, experienced a surge in popularity in 2020, as people were confined to their homes and had limited options for accessing medical care. Patients can access basic consultations, prescriptions, and referrals through telemedicine platforms. Teladoc helped provide that, but the company's fortunes turned in 2021. Demand for its services declined as government-imposed lockdown measures expired. The company also experienced consistent, and sometimes significant, net losses. Furthermore, BetterHelp, Teladoc's virtual therapy service and one of its main growth drivers during this period, also started facing challenges. BetterHelp encountered stiff competition, which ate into its market share. Due to all these issues, Teladoc's revenue has been growing very slowly -- if at all -- for the past few quarters, and the company remains unprofitable. Teladoc is looking to turn things around. One bright spot in the company's recent financial results has been its international expansion efforts. International revenue has been growing at a faster rate than in the rest of its business. If it can continue setting roots in countries outside the U.S., it could exploit meaningful growth opportunities there, or so the argument goes. Since the company's ecosystem remains deep -- with approximately 102 million integrated-care members -- Teladoc also hopes that it can grow revenue by cross-selling additional products to its existing members. While these plans sound good in theory, it's doubtful that Teladoc can pull them off. The telehealth specialist's efforts abroad might increase its already high expenses and make it harder for the company to turn profitable. And while cross-selling more products to existing members might be a great idea, Teladoc has failed to make meaningful progress in the past few years through this route. Maybe the company will eventually turn that around, but there's little reason to believe it will. The stock looks likely to remain southbound for some time, which is why it's best to avoid it. 2. Tilray Brands Tilray is a leader in the cannabis industry. The company offers a suite of products across both recreational and medical channels in Canada, the U.S., Germany, and several other countries. In Canada, Tilray still has the leading market share. However, none of that has allowed the company to perform well in recent years. It's not entirely Tilray's fault, since the cannabis industry faces significant regulatory challenges in the U.S.; the substance remains illegal at the federal level. Even in Canada, where medical and recreational uses of cannabis are legal, there have been challenges for the business, including oversupply. Although Tilray has the leading market share in Canada, the landscape has been challenging enough that it hasn't been able to grow its top and bottom lines consistently. In fairness, Tilray is now a fairly diversified company. It has expanded its craft brewing business, and also purchases and resells various pharmaceutical products in Germany through its distribution segment. The final business unit, "wellness," involves the production and sale of hemp-based foods. That said, diversification has had little impact on improving Tilray's financial results. So the company continues to rely on potential regulatory progress in the cannabis market. CEO Irwin Simon thinks recreational uses of cannabis will be legal in the U.S. by the end of President Donald Trump's second term. That's one reason the company expanded its craft brewing business in the U.S. through acquisition -- so it can sell drinks infused with THC and CBD when that happens. Tilray hopes that once legalization lands, it will be able to hit the ground running and dominate the markets for both recreational cannabis and cannabis-infused drinks, thanks to its existing footprint. However, there's no guarantee that this scenario will materialize anytime soon. While Tilray's shares recently soared on news that Trump could reclassify marijuana from a Schedule I substance to Schedule III, that's some ways away from federal legalization. It would be progress, to be clear. Schedule I drugs are considered to have the highest potential for abuse; that's not the case for Schedule III substances. However, marijuana would remain a controlled substance, still subject to heavy regulations at the federal level. But even under Simon's best-case scenario -- not just rescheduling but full-blown legalization -- we learned from our neighbors to the north that it's no guarantee of success for cannabis players. Tilray could encounter many of the same issues it faced in Canada. These included an initially complicated retail licensing system, stiff competition, and oversupply. In short, there's little hope that Tilray can bounce back anytime soon. The stock isn't worth investing in today. Should you buy stock in Teladoc Health right now? Before you buy stock in Teladoc Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Teladoc Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Teladoc Health. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy. 2 Stocks Down More Than 90% That Still Aren't Worth Buying was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
25 minutes ago
- Business Wire
Momentus Announces a Warrant Inducement Transaction for $2.7 Million in Gross Proceeds
SAN JOSE, Calif.--(BUSINESS WIRE)--Momentus Inc. (NASDAQ: MNTS) ("Momentus" or the "Company"), a leading U.S. commercial space firm specializing in satellite solutions, in-space transportation, and orbital infrastructure, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of (i) the October 2024 warrants to purchase up to 357,143 shares of common stock, (ii) the December 2024 warrants to purchase up to 800,000 shares of common stock, and (iii) the February 2025 warrants to purchase up to 1,273,886 shares of common stock, for a total of 2,431,029 warrants (together, the ' Existing Warrants '). The Existing Warrants will be exercised at a reduced exercise price of $1.11 for gross cash proceeds of approximately $2.7 million, before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. In consideration for the immediate exercise in full of the Existing Warrants, the investor will receive in a private placement new August 2025 Class A unregistered warrants to purchase up to 4,862,058 shares of common stock (the ' New Warrants '). The New Warrants will have an exercise price of $1.11 and will be initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained. The New Warrants will expire five years from the date of such approval. The closing of the warrant inducement transaction is expected to occur on or about August 14, 2025, subject to satisfaction of customary closing conditions. A.G.P./Alliance Global Partners acted as the exclusive financial advisor in connection with the transaction. The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act and, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Momentus Momentus is a U.S. commercial space company offering satellites, satellite components, and in-space transportation and infrastructure services. The Company offers satellites to support government and commercial customers for missions like communications, missile tracking, and cutting-edge science missions. Momentus offers services such as hosted payloads, support for in-space assembly, on-orbit servicing and refueling, and transportation of satellites to specific orbits. Forward-Looking Statements This press release contains certain statements that may constitute 'forward-looking statements' for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the expected closing of the Offering, the intended use of proceeds and fulfillment of customary closing conditions. Momentus or its management team's expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus' control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and uncertainties included under the heading 'Risk Factors' in the Annual Report on Form 10-K filed by the Company on June 6, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the 'SEC'), accessible on the SEC's website at and the Investor Relations section of our website at Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
